Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Noncanonical Transcription and Splicing Shape the Colorectal Cancer Immunopeptidome in MSI and MSS Tumors.

Molecular & cellular proteomics : MCP·2026
Same author

Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders.

Open forum infectious diseases·2026
Same author

CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling.

Cell reports·2025
Same author

Transgenic inducible MHC I overexpression in mouse alveolar type 2 cells.

Transgenic research·2025
Same author

Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer.

Nature cancer·2025
Same author

Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.

Current oncology (Toronto, Ont.)·2025
Same journal

Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming.

Blood·2026
Same journal

A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.

Blood·2026
Same journal

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same journal

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Blood·2026
Same journal

CD4+CD25+FOXP3+ Regulatory T Cells to Protect Against Graft Versus Host Disease.

Blood·2026
Same journal

Arterial iron regulates vasodilation during anemia via endothelial holo α-globin.

Blood·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Next-generation leukemia immunotherapy.

Krystel Vincent1, Denis-Claude Roy, Claude Perreault

  • 1Institute for Research in Immunology and Cancer, Universite de Montreal, Montreal, Canada.

Blood
|July 8, 2011
PubMed
Summary
This summary is machine-generated.

The graft-versus-leukemia (GVL) effect shows immune cells can fight leukemia. Targeted T-cell immunotherapy offers a promising, less toxic future for leukemia treatment.

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: May 31, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

  • Immunology
  • Oncology
  • Cancer immunotherapy

Background:

  • Allogeneic hematopoietic cell transplantation revealed the graft-versus-leukemia (GVL) effect, demonstrating immune cells' cancer-curing potential.
  • Conventional GVL induction via transplantation is toxic and suboptimal for leukemia immunotherapy.
  • Despite decades of research, GVL induction and manipulation methods have seen little advancement.

Purpose of the Study:

  • To explore antigen-targeted adoptive T-cell immunotherapy as a future strategy for leukemia treatment.
  • To discuss specific approaches for enhancing GVL effects while minimizing graft-versus-host disease (GVHD).

Main Methods:

  • Review of preclinical and clinical studies on T-cell therapies.
  • Analysis of strategies involving T cells primed against specific tumor antigens.
  • Examination of different antigen targets and T-cell receptor types.

Main Results:

  • Preclinical and clinical data suggest T cells targeting single antigens can boost GVL effects.
  • This approach holds the potential to enhance anti-leukemia activity without inducing significant GVHD.

Conclusions:

  • Antigen-targeted adoptive T-cell immunotherapy represents a significant advancement in leukemia immunotherapy.
  • Future strategies will focus on optimizing target antigens and T-cell receptors for enhanced efficacy and safety.